Insider Trading Alert - MDAS, WNR, PG, VPRT And PRGO Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 26, 2013, 184 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $199.71 to $214,535,257.08.

Highlighted Stocks Traded by Insiders:

MedAssets (MDAS) - FREE Research Report

Rutherford John C who is Director at MedAssets sold 13,000 shares at $21.41 on Nov. 26, 2013. Following this transaction, the Director owned 17,832 shares meaning that the stake was reduced by 42.16% with the 13,000 share transaction.

The shares most recently traded at $21.72, up $0.31, or 1.44% since the insider transaction. Historical insider transactions for MedAssets go as follows:

  • 4-Week # shares sold: 212,000
  • 12-Week # shares sold: 216,000
  • 24-Week # shares sold: 328,527

The average volume for MedAssets has been 544,300 shares per day over the past 30 days. MedAssets has a market cap of $1.3 billion and is part of the technology sector and computer software & services industry. Shares are up 27.55% year to date as of the close of trading on Tuesday.

MedAssets, Inc., a financial and performance improvement company, provides technology-enabled products and services for hospitals, health systems, and other ancillary healthcare providers in the United States. The company has a P/E ratio of 305.6. Currently there are 11 analysts that rate MedAssets a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDAS - FREE

TheStreet Quant Ratings rates MedAssets as a hold. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income and revenue growth. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk, disappointing return on equity and weak operating cash flow. Get the full MedAssets Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

New Lifetime High Reached By MedAssets (MDAS)

MedAssets (MDAS) Reaches New Lifetime High Today

MedAssets (MDAS) Stock Gains on Sale to Pamplona Capital Management

Today MedAssets (MDAS) Hits New Lifetime High

Analysts' Actions -- Apple, Disney, Hershey and More